Lanthier P L, Morgan M Y
Gut. 1985 Apr;26(4):415-20. doi: 10.1136/gut.26.4.415.
Lactulose is currently the drug of choice for the treatment of hepatic encephalopathy. It is, however, only available as a syrup which is contaminated with other sugars. Consequently patients may express aversion to its excessively sweet taste and many experience nausea because of its hyperosmolarity. Lactitol is a disaccharide analogue of lactulose which can be produced as a pure crystalline powder with a low relative sweetness. Theoretically it should have the same therapeutic effects as lactulose but fewer side effects. Five patients with chronic hepatic encephalopathy on maintenance lactulose were monitored clinically, psychometrically, and by measurement of venous blood ammonia, electroencephalogram mean cycle frequency, and cerebral blood flow during three months treatment with lactulose and a similar period on lactitol. Lactitol was at least as efficacious as lactulose but was more acceptable because its cathartic effect was more predictable, its formulation was more convenient and its less sweet taste preferred. Lactitol is the ideal successor to lactulose for treatment of this condition.
乳果糖是目前治疗肝性脑病的首选药物。然而,它仅以糖浆形式存在,且被其他糖类污染。因此,患者可能会因其过甜的味道而表现出厌恶,许多人还会因其高渗性而感到恶心。乳糖醇是乳果糖的二糖类似物,可制成相对甜度较低的纯结晶粉末。理论上,它应具有与乳果糖相同的治疗效果,但副作用更少。对5例接受维持性乳果糖治疗的慢性肝性脑病患者,在使用乳果糖治疗三个月以及使用乳糖醇治疗类似时长的期间,进行了临床、心理测量监测,并测量了静脉血氨、脑电图平均周期频率和脑血流量。乳糖醇至少与乳果糖一样有效,但更易被接受,因为其导泻作用更可预测,剂型更方便,且味道较不甜更受青睐。乳糖醇是治疗这种疾病的乳果糖的理想替代品。